STAT3-Luc/EF1α-mCherry Reporter Cell Line - HEK293

STAT3-Luc/EF1α-mCherry Reporter Cell Line - HEK293 is a human embryonic kidney 293 cell line engineered to provide sensitive monitoring of signal transducer and activator of transcription 3 (STAT3) pathway activity. The cells contain a firefly luciferase reporter driven by STAT3-responsive elements, enabling quantification of STAT3-dependent transcriptional activation through a luminescence-based readout. In parallel, constitutive expression of mCherry under the EF1α promoter provides a stable red fluorescent signal for cell visualization, normalization, and assessment of cell number or transduction status. This dual-reporter design combines pathway-specific functional measurement with a convenient fluorescent reference in a robust and widely used HEK293 cellular background. The cell line is suitable for routine culture and offers a reproducible platform for evaluating changes in STAT3 signaling induced by cytokines, growth factors, small molecules, biologics, or genetic perturbations.

This reporter cell line is particularly useful for screening and characterizing STAT3 agonists, inhibitors, and modulators. It can be employed in drug discovery programs to identify compounds capable of inhibiting aberrant STAT3 activation—a signaling event closely linked to inflammation, immune regulation, fibrosis, and tumor progression. Following stimulation with relevant upstream activators, the degree of STAT3 pathway activation or inhibition can be determined by measuring luciferase activity. The constitutive expression of an mCherry signal facilitates fluorescence imaging, cell tracking, normalization based on cell viability, and experimental quality control, making it especially well-suited for multiplexed assays or high-content analysis workflows. Beyond compound screening, this cell line can also be used to study receptor-mediated signaling, kinase activity, cytokine responses, the effects of CRISPR-based gene editing, RNA interference experiments, and the mechanisms underlying the development of resistance to STAT3-targeted therapies.